BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tuspetinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tuspetinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03850574-3101@assetmemo.bio
DTSTAMP:20261121T005453Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tuspetinib: Phase 1/2 readout est. (NCT03850574)
DESCRIPTION:Tuspetinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Clinic
 al Trial to Evaluate the Safety\, Tolerability\, Pharmacokinetics and Phar
 macodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refracto
 ry Acute Myeloid Leukemia\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tuspetinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03850574
URL:https://assetmemo.bio/drug/tuspetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
